You are a writer at a medical communications agency supporting development of the first draft of a manuscript reporting primary results from a phase 3 clinical trial. At your client’s request, you are using the pharmaceutical company’s internally developed generative AI tool as part of the drafting process.
Initially, the tool performs well, but as you develop the manuscript, you notice that it occasionally misinterprets study findings, overstates the clinical relevance of certain results, and inconsistently summarizes safety data. These issues can be corrected with careful human review, but doing so substantially reduces the expected efficiency gains. The publication timeline is tied to an upcoming scientific congress, and any significant delay could affect the planned communication strategy.
Your client explains that the AI platform has been approved for internal use and is expected to be used on all publication projects. Reverting entirely to manual drafting would likely affect project timelines and budget. The authors have not yet reviewed the draft and are unaware of the issues you have identified.
What Would You Do?
A. Escalate your concerns through both your own organization’s leadership and the client’s publication or compliance teams, because the observed problems suggest broader governance issues that extend beyond a single manuscript.
B. Ask the client to arrange an independent scientific review of AI-generated sections before the manuscript is shared with authors, while continuing to use the tool during the current project.
C. Immediately inform the client of your concerns and recommend suspending use of the AI tool for this manuscript until its performance can be evaluated further, even if this affects timelines and budget.
D. Continue using the AI tool tasks to develop the first draft while implementing enhanced human review and documenting all substantive AI-generated errors and corrections. Discuss your findings with the client and recommend improvements to the tool before it is used to draft future manuscripts.
This poll is now closed. Thank you for participating. Results and insights will be published soon.
